Dapagliflozin for treating heart failure with preserved ejection fraction ID1648
In development [GID-TA10942] Expected publication date: TBC
Search results
553 results
-
-
Ranibizumab port delivery system for treating wet age-related macular degeneration [ID3983]
In development [GID-TA10879] Expected publication date: TBC
-
Obesity - phentermine (with topiramate) [ID543]
In development [GID-TAG439] Expected publication date: TBC
-
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
In development [GID-TA10322] Expected publication date: TBC
-
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development [GID-TA10489] Expected publication date: TBC
-
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
In development [GID-TAG424] Expected publication date: TBC
-
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
In development [GID-TAG433] Expected publication date: TBC
-
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
In development [GID-TA10363] Expected publication date: TBC
-
Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]
In development [GID-TA10271] Expected publication date: TBC
-
Hypercholesterolemia - mipomersen [ID524]
In development [GID-TAG437] Expected publication date: TBC
-
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
-
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]
In development [GID-TAG369] Expected publication date: TBC
-
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]
In development [GID-TAG337] Expected publication date: TBC
-
Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]
In development [GID-TA10566] Expected publication date: TBC
-
Lung cancer (non-small-cell) - cetuximab [ID9]
In development [GID-TAG395] Expected publication date: TBC
-
Generalised anxiety disorder - quetiapine [ID347]
In development [GID-TAG421] Expected publication date: TBC
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
In development [GID-TA10311] Expected publication date: TBC
-
Peezy Midstream for urine collection (MT446)
In development [GID-MT538] Expected publication date: TBC
-
Mobocertinib for treating EGFR Exon 20 insertion-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3984]
In development [GID-TA10881] Expected publication date: 12 October 2022
-
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
In development [GID-TA10637] Expected publication date: TBC
-
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
In development [GID-HST10037] Expected publication date: TBC
-
Amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy [ID3836]
In development [GID-TA10729] Expected publication date: 12 October 2022
-
Alcohol-use disorders: prevention (update)
In development [GID-NG10299] Expected publication date: TBC
-
Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 06 July 2022
-
Empagliflozin for treating chronic heart failure with preserved ejection fraction [ID3945]
In development [GID-TA10946] Expected publication date: TBC
-
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]
In development [GID-TA10635] Expected publication date: TBC
-
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455
In development [GID-TA10356] Expected publication date: TBC
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604
In development [GID-TA10518] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: TBC
-
Systemic lupus erythematosus - prasterone [ID392]
In development [GID-TAG373] Expected publication date: TBC
-
Stroke rehabilitation in adults
In development [GID-NG10175] Expected publication date: 18 October 2023
-
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development [GID-TA10467] Expected publication date: TBC
-
Lasmiditan for treating acute migraine [ID3759]
In development [GID-TA10807] Expected publication date: 29 March 2023
-
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
In development [GID-TA10598] Expected publication date: TBC
-
Glioblastoma - bevacizumab [ID80]
In development [GID-TAG413] Expected publication date: TBC
-
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]
In development [GID-TA10579] Expected publication date: 19 October 2022
-
SACT
In development [GID-NG10184] Expected publication date: TBC
-
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178
In development [GID-TA10199] Expected publication date: TBC
-
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]
In development [GID-TAG436] Expected publication date: TBC
-
Weight Management: preventing, assessing and managing overweight and obesity (update)
In development [GID-NG10182] Expected publication date: 22 June 2023
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]
In development [GID-TA10544] Expected publication date: TBC
-
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404
In development [GID-TA10327] Expected publication date: TBC
-
Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]
In development [GID-TA10341] Expected publication date: TBC
-
Spasticity (after stroke) - botulinum toxin type A [ID768]
In development [GID-TAG499] Expected publication date: TBC
-
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)
In development [GID-TA10337] Expected publication date: 19 February 2020
-
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997
In development [GID-TA10382] Expected publication date: TBC
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC
-
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]
In development [GID-TAG278] Expected publication date: TBC